




# GENova Biotherapeutics

*GENova Biotherapeutics is going to go through the roof by using the newest cancer research in the fight against cancer!*



**GENOVA**  
BIOTHERAPEUTICS, INC

## » Mission

GENova Biotherapeutics, Inc. will create the next generation of targeted human therapeutics – safe medicine that works against a variety of cancers and infectious diseases.

GENova Biotherapeutics is a biotechnological drug development company with a strict focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings.

Each and every product candidate targets problem areas with considerable unmet need and ditto market potential. Subsequent inexpensive value-addition benefits both patients and stakeholders.

Fully developed our efficient programmes are then transferred to larger organizations, these being either other biotech companies and/or Big Pharma with infrastructures large enough to bring the products to market in a big scale.

In GENova Biotherapeutics we dedicate all our efforts in the development and commercial licensure of novel therapeutic proteins disrupting the growth of cancers. A prostate cancer target and a breast cancer target are included in our patented drug and product portfolio, as well as a promising acquisition pipeline. Not only do all our product candidates target disease indications which represent a significant unmet need, they also have substantial potential market values.

GENova Biotherapeutics follows an outlicensing strategy whereby programmes are outlicensed at the preclinical stage, Phase I, to organizations with infrastructures large enough to bring the products to market in a big scale.

Therapeutic focus and indication areas:  
1. Prostate cancer  
2. Breast cancer  
3. Colorectal cancer

*“A \$10,000 investment in GENova Biotherapeutics could yield you as much as \$100,000 in just 12 months. How? Read on...”*

*“The Company’s objectives are to accelerate the drug development process, ensuring patients enhanced benefits and, at the same time, maximizing shareholder value”*

## » Business strategy

Today, when it comes to biotech and pharmaceutical business strategy, early stage partnering is a core component as it that allows companies to access promising new and emerging compounds and technologies.

In the pharmaceutical industry dealmaking is growing all the time. By next year big pharmaceutical companies are forecast to receive around 40-50% of their revenue from in-licensed products (Pharmalicensing, 2006). In addition, the dealmaking balance has moved from the later stages of development to the earliest stages, where deals have not only increased in number but also in value.

*“By 2010 big pharmaceutical companies are forecast to receive around 40-50% of their revenue from in-licensed products”*



**The Opening BULL** keeps you ahead of Wall Street. We go off the beaten path to locate that unique investment opportunity that can truly make your investment skyrocket before the rest of Wall Street gets in on it!



**What you should know** about cancer and how GENova Biotherapeutics is going to use the newest therapeutic technologies and biomarkers to do something about it!



**How GENova Biotherapeutics** is going to turn your investment into a fortune using the newest cancer research, and why you can expect up to 1,000% yield on your investment!

# Cancer Kills Millions Every Year!

*Cancer is one of the biggest killer diseases of the modern world, but now brand new research brings the cure to cancer closer than ever before. GENova biotherapeutics is a shooting star when it comes to applying this new research, making it into both usable and profitable products!*

Being diagnosed with cancer is a life-shattering experience for several reasons: Doctors have identified several risk factors, but at the same time people leading perfectly healthy lives still get cancer. Second, being diagnosed with cancer is often seen as a death sentence. And finally, the only answer to cancer today is invasive surgery, radiation treatment or chemotherapy, three not very pleasant

We all know about the adverse side-effects to radiation treatment and chemotherapy: loss of appetite, loss of hair, diminished libido, constant nausea etc., and often there's only a remote chance that it will actually stop the cancer.


In fact, some cancer patients actually refrain from receiving life-prolonging treatment, simply because the side-effects from the treatment are too adverse! 24.6 million people have cancer, and about 8 million die every year from the disease, and the two predominant kinds of cancer are prostate cancer in men, and breast cancer in women.

These two cancer types account for about 50% of all cancer cases. The cancer treatment market is a billion dollar market, and huge bioscientific breakthroughs in the past 12 months may in fact be heralding new kinds of cures for cancer.

It is in exactly this field that GENova Biotherapeutics is at the very forefront!

*"...The multi-billion dollar cancer treatment market is exploding, growing at 20% per annum! And the drug targets from GENova Biotherapeutics have the biggest potential we have ever seen!"*

## GENova Biotherapeutics IP sourcing and development




**GENova Biotherapeutics has the biggest shot at locating the answer to cancer!**

## GENova Biotherapeutics Employs Newest Research!

*For decades, cancer research has been concentrated on diagnosing and preventing cancer, whereas the research in treatment has been at a stand-still. But in the last 12 months, there has been a huge leap forward in the search for treatments for cancer!*

### Product development lifecycle



*"...The key is to trace cancer cells to their origin – which is the very first stem cell from which the malignant cell arose..."*

For decades, radiation and chemotherapy have been used to treat cancer, both radically disruptive to the human body, virtually killing the immune system in order to stop the cancer. This is about as elegant as shooting at birds with a haubitzer - it may work, but it sure as hell isn't pretty!

Very recent research, some of it not even known just 12 months ago, may lead to much more elegant cures for cancer with significantly fewer side-effects, leading to a higher quality of life for the patients and a much better survival rate.

GENova Biotherapeutics has acquired patents for therapeutic drug targets that work on breast cancer and prostate cancer. These drug targets have been developed using the very latest therapeutic technologies: With the new therapeutic technologies you can now fingerprint individual cells, making it possible to locate the specific cell from which the cancer started spreading.

Being able to identify the stem cell makes it possible to target the cancer at the root. This in turn enables the development of tailor-made drugs targeted at the specific type of cancer, located in that particular individual!

This and other groundbreaking findings, make GENova Biotherapeutics the best investment at the very moment!

**With a fast-track to FDA approval, the life cycle is improved considerably!**

# Drug Targets with Huge Potential!

GENova Biotherapeutic's two unique proprietary anti-tumor drug targets aimed at prostate cancer and breast cancer are extremely promising, as they apply the very latest bioscientific progress, making it very probable that they will be the very key in more efficacious cures for these two most widespread and lethal cancer types.

Both Tetanolic, the drug target against breast cancer, and Prostaglanin, aimed at prostate cancer, make use of brand new discoveries that stop cancer cell growth, or that overcome the inherent resistance in cancer cells, or even kill them!

And with both anti-tumor drug targets, the very latest bioscientific technologies can be applied, targeting specific cells directly, making them even more efficacious.

Being the company with the key to the two most prevalent types of cancer is of immense value.

So not only will an investment in GENova Biotherapeutics benefit your health but also your pocket.

That is why we believe GENova Biotherapeutics is the hottest bioscientific share at the moment, with prospects of immense yields in the near future!

*"GENova Biotherapeutics receiving billions in license fees will skyrocket the share value – we believe it will be in excess of 1,000%"*



## \$215 Billion for Licensing!

The big pharmaceutical companies have imploding drug development pipelines, and consequently they are searching high and low for that new Fontex or Viagra. They have \$215 billion ready to use on licensing of new drug targets.

GENova Biotherapeutics has some of the most promising drug targets at the moment and can expect to retrieve mind-blowing licensing fees: GENova Biotherapeutics can expect \$100 million per annum in milestone payments during clinical trials, and up to \$700 million per annum in the years following commercialization.

And recent technological breakthroughs in the use of biomarkers enable accelerated drug development and FDA approval; this prolongs the life-cycle of the drug targets, and consequently leads to even higher licensing fees! GENova Biotherapeutics has a pipeline with yet three other very exciting new drug targets.

Meanwhile, the use of contract research organizations in the U.S., Europe and India ensures minimal overheads, while the management team with over 100 years of combined experience ensures all milestones are reached and surpassed.

No other therapeutic company has this potential!

**The new revolution in Cancer treatment – possibly the biggest development ever!**

For many years, progress in cancer research has been slow. Now, with the progress shown by GENova Biotherapeutics, cancer treatment will make a quantum leap forward!


This will not only benefit the millions of people with cancer, but will also change the biopharmaceutical playing field. Holding some of the keys to two of the most prevalent cancer forms, making it possible to target malignant cancer cells without any of the usual horrible side-effects will not only benefit the patients, but also the company behind this progress.

GENova Biotherapeutics is at the moment a relatively small and unknown therapeutic company, but advances such as those described in the previous pages will lead to an explosion in the share price of unequalled proportions!

When a Big Pharmaceutical company makes a so enormous breakthrough such as this, you can perhaps expect a doubling in their share price, as previous gains and ongoing sales are also reflected in their share price. But with a company such as GENova Biotherapeutics, which is undervalued at the moment, we expect a ten-fold increase in the share price during the next year!

Get in on the ground floor, and turn that \$10,000 dollar investment into \$100,000 in 12 months!

GENova Biotherapeutics Investment and profit through the drug lifecycle



**GENova Biotherapeutics will receive billions in licensing fees from the drug targets!**

**Hot pick from the opening bull:  
GENova Biotherapeutics GVPB.OB  
www.GENovabio.com**



# GENova Biotherapeutics is going to go through the roof!

## Blockbuster Drug Targets!

*As you are probably aware of by now, GENova Biotherapeutics has some extremely impressive drug targets:*

The two drug targets against breast cancer and prostate cancer are most promising, as they are truly ground breaking, utilizing breakthroughs that were not known just 12 months ago!

The drug targets will make it possible to fight cancer without invasive surgery, radiology or chemotherapy, some of the most radical treatments available, having many dreaded side-effects. Chemotherapy virtually kills the body's own immune system, making the patient susceptible to all kinds of terrible ailments while the doctors try to contain or treat the cancer

itself. And often with little effect: GENova Biotherapeutics's drug targets have none of those side-effects. Millions of people are no longer going to have to suffer from these horrible side-effects but can receive a treatment much less disruptive to their bodies and their lives as a whole.

GENova Biotherapeutics's drug targets are probably the first true quantum leap forward in cancer treatment in years! And with a cancer treatment market growing at 20% per annum and a fast track to FDA-approval, advances such as these are going to

benefit the investors handsomely. In all, we believe this gives GENova Biotherapeutics a humongous potential and makes it one of the most interesting therapeutic companies right now!

The patents of GENova Biotherapeutics make it a very profitable investment already, but it will be in the next 12 months that it will truly soar!

Get in on it while you can!

---

*"Upon out-licensing of their very promising drug targets, we expect a ten-fold increase in the share value..."*

---

## A Blockbuster Company!

*GENova Biotherapeutics has the biggest profit potential when it comes to the new advances in cancer research:*

Impressive drug targets aside, GENova Biotherapeutics is a profitable investment for several other reasons:

GENova Biotherapeutics focuses solely on development of non-invasive and nondisruptive treatments for cancer; a market covering almost 25 million people, and a market that is growing at 20% per annum!

GENova Biotherapeutic's management team and advisory board have over 100 years of combined know-how, as well as a proven track-record.

The market itself is ripe: The Big Pharmaceutical companies are running out of profitable products, and due to inertia and an old-fashioned approach, they can't come up with new and profitable drugs in their own research pipelines. Meanwhile, the Big Pharmaceutical companies have stashed over \$215 billion away. Therefore, the Big Pharmaceutical companies are willing to pay \$100 million per annum for a promising drug target while it is in clinical trial, as well as subsequent license fees of up to \$700 million per annum upon commercialization!

GENova Biotherapeutic's two (and three more in the pipeline) of those most promising drug targets will make them go crazy!

GENova Biotherapeutics receiving several billion dollars for just one single drug target will skyrocket the share price to ten times its present value! Add it to your portfolio while you can!

Call your broker immediately and ask about GENova Biotherapeutics, GVBPOB so you can get in on this unique investment opportunity now before it takes off and goes through the roof!

**IMPORTANT NOTICE AND DISCLAIMER:** This document does not purport to provide an analysis of any company's financial position, operations or prospects and is not to be construed as a recommendation or as an offer or solicitation to buy or sell any security. GENova Biotherapeutics, Inc., the company featured in this issue, appears as paid advertising paid for by an unaffiliated third party to provide public awareness of the company. All information appearing in this document is taken from publicly available sources and from information provided by GENova Biotherapeutics, Inc., which it believes is already public and to US Distribution Inc. Although US Distribution Inc and its editors do believe this information to be accurate and reliable, US Distribution Inc nor its editors have independently verified any information contained in this advertisement and neither US Distribution Inc nor its editors make any warranty with respect to the accuracy of any information contained herein. US Distribution Inc, The Opening Bull and its editors expressly disclaim any liability resulting from how readers may choose to utilize the contents of this paid advertisement. Readers should perform their own due diligence and are strongly urged to independently verify all statements made in this or any other paid advertisement. Any investment should be made only after consulting with a qualified professional investment advisor and after reviewing the publicly available financial statements of and other information about, the company and verifying that the investment is appropriate and suitable for you. You can obtain more information about GENova Biotherapeutics, Inc. from its website at [www.GENovabio.com](http://www.GENovabio.com). GENova Biotherapeutics, Inc. is a reporting company under the Securities Exchange Act of 1934, as amended, and its periodic and other reports made under that law are publicly available from the Securities and Exchange Commission at their website at <http://www.sec.gov/edgar/searchedgar/webusers.htm>. General investor information about publicly traded companies like GENova Biotherapeutics, Inc. is available from the Securities and Exchange Commission's website at [www.sec.gov](http://www.sec.gov) or from the National Association of Securities Dealers, Inc.'s website at [www.nasdaq.com](http://www.nasdaq.com). Many states have established rules requiring the approval of a security by a state securities administrator. Check with [www.nasaa.org](http://www.nasaa.org) or call your state securities administrator to determine whether a particular security is licensed for sale in your state. Many companies have filed information with state securities regulators and many companies will supply prospective investors with additional information upon request. US Distribution Inc has received and managed a total production budget of one hundred thousand dollars (\$100,000) from an unaffiliated third party for this print advertising effort and will retain any amounts over and above the cost of production, newsletter editorial services, copywriting services, postage, mailing and other distribution expenses as a fee for its services. US Distribution Inc does not own any securities in GENova Biotherapeutics, Inc., and will not buy, sell, or offer to buy or sell any securities in GENova Biotherapeutics, Inc. Investing in securities is highly speculative and carries a great deal of risk, especially as to new companies with limited operations and no history of earnings. This paid advertisement contains forward-looking statements regarding GENova Biotherapeutics, Inc., its business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions created by these laws. Wherein this document expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to, the size and growth of the market for GENova Biotherapeutics, Inc.'s proprietary patented drug targets, obtaining the necessary contractual relationships to produce and market these drug targets; regulatory approvals; the ability of the company to continue funding its capital requirements; development of competing technologies; effects of short-selling and other market pressures, and other factors. For a more detailed discussion of such risks and other factors, please contact The Securities and Exchange Commission at [www.sec.gov](http://www.sec.gov).